34 citations
,
June 2015 in “Journal of cardiovascular pharmacology and therapeutics” Direct vasodilators and sympatholytic agents are still useful for certain conditions despite being less common due to side effects and newer drugs.
25 citations
,
October 2008 in “Chromatographia” A fast and accurate method was developed to measure alfuzosin and dutasteride in human plasma.
April 2018 in “The Journal of urology/The journal of urology” A new score can help predict which patients might have trouble urinating after prostate surgery.
January 2015 in “International Journal of Nanomedicine” Anionic squarticles can effectively counteract amitriptyline overdose, improving survival rates.
March 2015 in “The Journal of Urology” Finasteride reduces PSA levels by around 40-50% in BPH patients.
March 2026 in “The Aging Male” PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
4 citations
,
September 2002 in “Der Urologe” Combination therapy is more effective for prostate volumes over 60 ml.
16 citations
,
October 2017 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Dutasteride may protect the brain in early Parkinson's disease.
Tamsulosin and finasteride together effectively slow down and prevent BPH progression.
4 citations
,
October 2025 in “Science Advances” VCAM1 appears early in kidney injury and signals future nephron loss.
1 citations
,
October 2002 in “The Journal of Urology”
27 citations
,
May 2019 in “American Journal of Clinical Dermatology” Antiandrogen therapy for hidradenitis suppurativa lacks strong evidence and needs more research.
April 2011 in “The FASEB Journal” Amlodipine impairs fertility in male rats by affecting sperm and testicular structure.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
May 2024 in “Reactions weekly” 59 citations
,
January 1976 in “Vitamins and hormones” Prostate cells have proteins that bind to specific hormones, which can increase protein production when activated by these hormones.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
5 citations
,
January 2014 in “Molecular Simulation” A new compound may treat benign prostatic hyperplasia better than finasteride.
21 citations
,
October 1978 in “The Journal of Clinical Pharmacology”
January 2018 in “Repositorio de Tesis - UNMSM” Physalis peruviana extract is more effective in treating benign prostatic hyperplasia in rats than finasteride and terazosine.
Different botulinum toxin products and concentrations can effectively reduce sweating, itching, bladder pressure, hair loss, and muscle spasms.
161 citations
,
August 2013 in “Journal of experimental botany” Certain inhibitors slow down plant growth by causing early cell specialization without changing the cell development pattern.
February 2023 in “Global Journal of Reproductive Medicine” Medical treatments for benign prostatic hyperplasia mainly relieve symptoms, while surgery is more effective but not always suitable for elderly patients.
Potassium channel openers like minoxidil boost hair growth.
97 citations
,
December 2011 in “New England Journal of Medicine” The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.
1 citations
,
June 2025 in “Journal of Allergy and Clinical Immunology Global” A young boy with Netherton syndrome improved significantly using IVIG, dupilumab, and dietary changes.